PODD · 10-Q · 2026Q2

INSULET CORP

Filed 2026-08-05 · Healthcare · View original filing on EDGAR

Ranked Events

• Share Repurchase ProgramImportance 77 · Surprise 82
  Insulet repurchased $300.0 million of common stock during the first six months of 2026, compared with $30.1 million in the prior-year period. The company repurchased 1.251 million shares during the six months ended…
• Capital Expenditures ProgramImportance 71 · Surprise 82
  Capital expenditures increased 83.8% to $56.8 million for the first six months of 2026 from $30.9 million in the prior-year period. Insulet invested an additional $8.3 million in developed software during the period,…
• Liquidity and Debt PositionImportance 71 · Surprise 48
  Cash and cash equivalents declined $181.2 million to $534.9 million at June 30, 2026 from $716.1 million at December 31, 2025. Net cash provided by operating activities was $202.2 million for the first six months,…
• FX / Currency ImpactImportance 70 · Surprise 56
  International Omnipod revenue increased $156.5 million, or 46.3%, to $494.6 million for the six months ended June 30, 2026. Currency exchange contributed a favorable 7.9% impact, while underlying growth was 38.4%.…
• International Omnipod Revenue GrowthImportance 69 · Surprise 56
  U.S. Omnipod revenue increased 20.1% to $544.1 million in the second quarter of 2026 and 24.0% to $1.060 billion for the first six months. International Omnipod revenue grew 35.5% to $251.8 million in the quarter and…
• International Market ExpansionImportance 66 · Surprise 74
  Insulet launched Omnipod 5 and Omnipod Discover in five Middle Eastern countries in February 2026 and launched the products in Spain in July 2026. The company is building international teams and advancing regulatory,…
• Trade Secret LitigationImportance 65 · Surprise 60
  Insulet obtained a $59.4 million damages award and worldwide permanent injunction against EOFlow defendants over misappropriation of four Omnipod-related trade secrets. On May 28, 2026, the Federal Circuit reversed the…
• Free Cash FlowImportance 64 · Surprise 56
  Free cash flow decreased $83.9 million, or 36.6%, to $145.4 million for the six months ended June 30, 2026 from $229.4 million. The decline resulted primarily from higher working-capital outflows and capital…
• End-Market Demand TrendsImportance 64 · Surprise 56
  Omnipod product revenue increased 24.6% in the second quarter and 30.3% in the first six months of 2026, driven primarily by higher sales volume and a growing customer base. U.S. Omnipod revenue grew 20.1% in the…
• Research and Development ExpenseImportance 64 · Surprise 56
  Research and development expense increased 20.0% to $88.1 million in the second quarter of 2026 and 33.7% to $177.8 million for the first six months. Selling, general and administrative expense increased 33.8% to…
• Semiconductor Purchase CommitmentImportance 60 · Surprise 48
  Insulet entered into a 2026 purchase agreement with NXP USA for semiconductor chips used in its products. The commitment totaled approximately $77.4 million as of June 30, 2026, exceeding the materiality threshold for…
• Operating Cash Flow TrendsImportance 59 · Surprise 48
  Operating cash flow was $202.2 million for the six months ended June 30, 2026, down from $260.3 million in the prior-year period. A $94.5 million working-capital outflow included a $76.9 million increase in accounts…
• Product Safety CorrectionsImportance 59 · Surprise 60
  During the six months ended June 30, 2026, Insulet issued two voluntary medical device corrections, in March and May, for separate manufacturing issues that could cause a tear in the cannula of certain Omnipod…
• Gross Margin DriversImportance 59 · Surprise 48
  Three-month cost of revenue increased $42.3 million, or 21.5%, to $239.1 million, while gross margin expanded 50 basis points to 70.2% from 69.7%. The quarterly margin improvement was primarily driven by manufacturing…
• Revenue Performance and MixImportance 59 · Surprise 48
  Total revenue increased 23.5% year over year to $801.7 million in the second quarter of 2026 from $649.1 million, and increased 28.4% to $1.563 billion for the six months ended June 30, 2026. Omnipod product revenue…
• Interest Rate OutlookImportance 57 · Surprise 64
  Interest expense was $28.2 million for the six months ended June 30, 2026, with higher expense from the 6.5% senior unsecured notes issued in March 2025 and interest-rate swaps renewed at higher rates in April 2025.…
• Inventory Build and Manufacturing ExpansionImportance 57 · Surprise 50
  Insulet increased inventories by $34.9 million during the first six months of 2026 as part of a planned build to satisfy growing demand. Capital expenditures increased to $56.8 million, primarily for machinery,…
• Drug Delivery Revenue DeclineImportance 51 · Surprise 64
  Drug Delivery revenue consists substantially of pod sales to Amgen for the Neulasta Onpro kit, which helps reduce infection risk after intensive chemotherapy. Revenue declined to $9.1 million for the first six months…
• Income Tax Rate ChangesImportance 51 · Surprise 64
  The effective tax rate was 19.7% for the first six months of 2026, down from 24.3% in the prior-year period. Income tax expense increased to $45.6 million from $18.6 million because pretax income increased to $231.7…
• Securities Fraud InvestigationImportance 44 · Surprise 60
  On July 2, 2026, a putative securities class action was filed in the U.S. District Court for the District of Massachusetts against Insulet and certain current and former executives and directors. The complaint alleges…

Revenue by Product (in millions)

Revenue by Geography (in millions)